Literature DB >> 28373440

Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.

Nikolaos Tsoukalas1, Eleni Aravantinou-Fatorou2, Maria Tolia3, Constantinos Giaginis4, Michail Galanopoulos5, Maria Kiakou5, Ioannis D Kostakis5, Eugene Dana4, Ioannis Vamvakaris4, Athanasios Korogiannos4, Evangelos Tsiambas5, Nikolaos Salemis5, George Kyrgias3, Andreas Karameris6, Stamatios Theocharis4.   

Abstract

BACKGROUND/AIM: Lung cancer is the first cause of cancer related deaths in both males and females. Epithelial-mesenchymal transition (EMT) is a reversible process by which epithelial cells transform to mesenchymal stem cells by losing their cell polarity and cell-to-cell adhesion, gaining migratory and invasive properties. High levels of E-cadherin are expressed in epithelial cells, whereas mesenchymal cells express high levels of N-cadherin, fibronectin and vimentin. The aim of this study was to evaluate the correlation between E-cadherin and vimentin expression and their clinical significance in non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: The immunohistochemical expression of E-cadherin, vimentin and Ki-67 was performed on tissue microarrays from NSCLC specimens obtained from 112 newly- diagnosed cases and were studied using classical pathological evaluation. Associations between E-cadherin, vimentin and Ki-67 expression, clinicopathological variables and survival were analyzed. In all cases, a value of p≤0.05 was considered significant.
RESULTS: Low E-cadherin expression was significantly correlated with tumor necrosis (p=0.019). Moreover, there was a trend for correlation between high E-cadherin expression and better overall survival (hazard ratio=1.02, and 95% confidence interval=0.45-1.87, p=0.091). There was also a significant negative correlation between vimentin expression and overall survival (hazard ratio=1.13, and 95% confidence interval=0.78-1.65, p=0.026). Additionally, there was a significant negative correlation between vimentin expression and grade I tumors (p=0.031). Finally, a positive correlation trend between vimentin expression and Ki-67 was found (p=0.073).
CONCLUSION: High E-cadherin and low vimentin expression correlate with better prognosis and overall survival. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  E-Cadherin; biomarker; epithelial mesenchymal transition (EMT); non-small-cell lung cancer (NSCLC); prognosis; vimentin

Mesh:

Substances:

Year:  2017        PMID: 28373440     DOI: 10.21873/anticanres.11510

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

Review 1.  Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer.

Authors:  Meysam Yousefi; Parisa Ghaffari; Rahim Nosrati; Sadegh Dehghani; Arash Salmaninejad; Yousef Jafari Abarghan; Seyed H Ghaffari
Journal:  Cell Oncol (Dordr)       Date:  2019-12-11       Impact factor: 6.730

2.  The MyoD family inhibitor domain-containing protein enhances the chemoresistance of cancer stem cells in the epithelial state by increasing β-catenin activity.

Authors:  Chao-Ju Chen; Chih-Jen Yang; Sheau-Fang Yang; Ming-Shyang Huang; Yu-Peng Liu
Journal:  Oncogene       Date:  2020-01-07       Impact factor: 9.867

3.  Berberine-loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro.

Authors:  Keshav R Paudel; Meenu Mehta; Geena Hew Suet Yin; Lee Li Yen; Vamshikrishna Malyla; Vyoma K Patel; Jithendra Panneerselvam; Thiagarajan Madheswaran; Ronan MacLoughlin; Niraj Kumar Jha; Piyush Kumar Gupta; Sachin Kumar Singh; Gaurav Gupta; Pradeep Kumar; Brian G Oliver; Philip M Hansbro; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Environ Sci Pollut Res Int       Date:  2022-02-16       Impact factor: 5.190

Review 4.  Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer.

Authors:  Antoine Legras; Nicolas Pécuchet; Sandrine Imbeaud; Karine Pallier; Audrey Didelot; Hélène Roussel; Laure Gibault; Elizabeth Fabre; Françoise Le Pimpec-Barthes; Pierre Laurent-Puig; Hélène Blons
Journal:  Cancers (Basel)       Date:  2017-08-03       Impact factor: 6.639

5.  Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC).

Authors:  Young Kwang Chae; Sangmin Chang; Taeyeong Ko; Jonathan Anker; Sarita Agte; Wade Iams; Wooyoung M Choi; Kyoungmin Lee; Marcelo Cruz
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

6.  Comprehensive analysis of spread through air spaces in lung adenocarcinoma and squamous cell carcinoma using the 8th edition AJCC/UICC staging system.

Authors:  Meng Jia; Shili Yu; Jiaqi Yu; Yuemin Li; Hongwen Gao; Ping-Li Sun
Journal:  BMC Cancer       Date:  2020-07-29       Impact factor: 4.430

7.  Clinicopathological, Radiological, and Molecular Features of Primary Lung Adenocarcinoma with Morule-Like Components.

Authors:  Li-Li Wang; Li Ding; Peng Zhao; Jing-Jing Guan; Xiao-Bin Ji; Xiao-Li Zhou; Shi-Hong Shao; Yu-Wei Zou; Wei-Wei Fu; Dong-Liang Lin
Journal:  Dis Markers       Date:  2021-06-12       Impact factor: 3.434

Review 8.  Acetylcholine signaling system in progression of lung cancers.

Authors:  Jamie R Friedman; Stephen D Richbart; Justin C Merritt; Kathleen C Brown; Nicholas A Nolan; Austin T Akers; Jamie K Lau; Zachary R Robateau; Sarah L Miles; Piyali Dasgupta
Journal:  Pharmacol Ther       Date:  2018-10-03       Impact factor: 13.400

Review 9.  MicroRNAs associated with therapy of non-small cell lung cancer.

Authors:  Junmi Lu; Yuting Zhan; Juan Feng; Jiadi Luo; Songqing Fan
Journal:  Int J Biol Sci       Date:  2018-03-10       Impact factor: 6.580

10.  Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer.

Authors:  Arik Bernard Schulze; Georg Evers; Dennis Görlich; Michael Mohr; Alessandro Marra; Ludger Hillejan; Jan Rehkämper; Lars Henning Schmidt; Birthe Heitkötter
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.